Wall Street Analysts Think Ocular Therapeutix ( OCUL ) Could Surge 82.48%: Read This Before Placing a Bet
The consensus price target hints at an 82.5% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ocular Therapeutix™ to Participate in November and December Investor Conferences - Ocular Therapeutix ( NASDAQ:OCUL )
BEDFORD, Mass., Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ:OCUL, "Ocular" ) ) , an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in November and December, 2025.
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BEDFORD, Mass., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ: OCUL, "Ocular" ) , an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired non-executive employee.
Ocular Therapeutix ( OCUL ) Reports Q3 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of +5.13% and +8.89%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights
Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability ...
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R - Ocular Therapeutix ( NASDAQ:OCUL )
SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA submission for AXPAXLI in wet AMD
Wall Street Analysts Believe Ocular Therapeutix ( OCUL ) Could Rally 82.93%: Here's is How to Trade
The consensus price target hints at an 82.9% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ocular Therapeutix ( OCUL ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Ocular Therapeutix (OCUL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday - BOK Financial ( NASDAQ:BOKF ) , Danaher ( NYSE:DHR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Securities raised Flex Ltd. ( NYSE:FLEX ) price target from $58 to $65.
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - Ocular Therapeutix ( NASDAQ:OCUL )
BEDFORD, Mass., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ:OCUL, "Ocular" ) ) , an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in October 2025.
Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock
BEDFORD, Mass., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( Nasdaq: OCUL ) ( "Ocular", the "Company" ) , an integrated biopharmaceutical company committed to redefining the retina experience, today announced the pricing of an underwritten offering of 37,909,018 shares of its ...
Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint - Ocular Therapeutix ( NASDAQ:OCUL )
SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026
Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint
SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date. topline data on track for ...
This Broadcom Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Broadcom ( NASDAQ:AVGO ) , Fractyl Health ( NASDAQ:GUTS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Chardan Capital analyst Daniil Gataulin initiated coverage on Ocular Therapeutix, Inc.
Looking At Ocular Therapeutix's Recent Unusual Options Activity - Ocular Therapeutix ( NASDAQ:OCUL )
High-rolling investors have positioned themselves bullish on Ocular Therapeutix OCUL, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
Ocular Therapeutix™ to Participate in September Investor and Scientific Conferences - Ocular Therapeutix ( NASDAQ:OCUL )
BEDFORD, Mass., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. OCUL "Ocular" ) ) , an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September 2025.
OCUL Sales Drop 18%
Ocular Therapeutix ( NASDAQ:OCUL ) , a biotechnology company developing therapies for eye diseases, reported its second quarter results on August 5, 2025. The earnings release pointed to a significant widening in net loss due to increased research and marketing investments.
Ocular Therapeutix ( OCUL ) Reports Q2 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -11.43% and -0.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights - Ocular Therapeutix ( NASDAQ:OCUL )
Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD SOL-1 remains on track for 1Q 2026 topline data SOL-R rescue criteria streamlined and simplified with topline data expected in 1H 2027 Planning to incorporate single long-term extension study ...
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
BEDFORD, Mass., July 22, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ: OCUL, "Ocular" ) , a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in July and August 2025.
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - Ocular Therapeutix ( NASDAQ:OCUL )
BEDFORD, Mass., July 22, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. OCUL "Ocular" ) ) , a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in July and August 2025.
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company - Ocular Therapeutix ( NASDAQ:OCUL )
BEDFORD, Mass., June 26, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. OCUL "Ocular" ) ) , a biopharmaceutical company committed to redefining the retina experience, announced the launch of its new corporate branding and website today, marking the next milestone of the Company's ...
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience ...
Ocular Therapeutix ( OCUL ) Moves 8.6% Higher: Will This Strength Last?
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday - Ambarella ( NASDAQ:AMBA ) , Amylyx Pharmaceuticals ( NASDAQ:AMLX )
U.S. stocks were higher, with the Dow Jones index gaining around 450 points on Tuesday. Shares of Carnival Corporation CCL rose sharply during Tuesday's session after the company reported better-than-expected second-quarter EPS and sales.
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit ( CTS ) 2025 - Ocular Therapeutix ( NASDAQ:OCUL )
BEDFORD, Mass., June 16, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. OCUL "Ocular" ) ) , a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2025, taking place on June 21, 2025, in Las ...
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit ( CTS ) 2025
BEDFORD, Mass., June 16, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ: OCUL, "Ocular" ) , a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2025, taking place on June 21, ...
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences
BEDFORD, Mass., May 14, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ: OCUL, "Ocular" ) , a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in the second half of May ...
Ocular Therapeutix ( OCUL ) Reports Q1 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -27.59% and 37.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Esperion Therapeutics ( ESPR ) to Report a Decline in Earnings: What to Look Out for
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences - Ocular Therapeutix ( NASDAQ:OCUL )
BEDFORD, Mass., April 29, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. OCUL "Ocular" ) ) , a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in the first half of May 2025.
Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025 - Ocular Therapeutix ( NASDAQ:OCUL )
BEDFORD, Mass., April 28, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. OCUL "Ocular" ) ) , a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter 2025 financial results on Monday, May 5, 2025 ...
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BEDFORD, Mass., April 11, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ: OCUL, "Ocular" ) , a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to its newly appointed Executive Director, Payer Access, ...
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sun Communities ( NYSE:SUI ) , Ocular Therapeutix ( NASDAQ:OCUL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Jefferies analyst Peter Abramowitz initiated coverage on Sun Communities, Inc.
Ocular Therapeutix™ to Participate in Two Investor Conferences in April
BEDFORD, Mass., March 31, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ: OCUL, "Ocular" ) , a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in April: ...
Ocular Therapeutix™ to Participate in Two Investor Conferences in April - Ocular Therapeutix ( NASDAQ:OCUL )
BEDFORD, Mass., March 31, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. OCUL "Ocular" ) ) , a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in April:
Why Ocular Therapeutix Was Bumping Higher This Week
The market was seeing Ocular Therapeutix ( NASDAQ: OCUL ) very positively this week, and that sunny view pushed the company's stock higher.As of Friday morning before market open, the eye care specialist's shares were up by nearly 5% in price week to date, according to data compiled by S&P ...
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside - Ocular Therapeutix ( NASDAQ:OCUL )
Ocular Therapeutix expects topline SOL-1 trial data for Axpaxli in Q4 2025. Analyst projects Axpaxli peak sales of $1.5B with 15-20% second-line share. Find out which stock just plummeted to the bottom of the new Benzinga Rankings. Updated daily-spot the biggest red flags before it's too late.
This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Northpointe Bancshares ( NYSE:NPB ) , Inuvo ( AMEX:INUV )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keefe, Bruyette & Woods analyst Damon Delmonte initiated coverage on Northpointe Bancshares, ...
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BEDFORD, Mass., March 07, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ: OCUL, "Ocular" ) , a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired employee.
Ocular Therapeutix ( OCUL ) Reports Q4 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -20.83% and 2.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Amneal ( AMRX ) Soars 6.0%: Is Further Upside Left in the Stock?
Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ocular Therapeutix™ to Present at Two Investor Conferences in March - Ocular Therapeutix ( NASDAQ:OCUL )
BEDFORD, Mass., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. OCUL "Ocular" ) ) , a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in March:
Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting
BEDFORD, Mass., Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ: OCUL, "Ocular" ) , a biopharmaceutical company committed to redefining the retina experience, today announced upcoming presentations at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on ...
Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation - Ocular Therapeutix ( NASDAQ:OCUL )
Company presentation scheduled on Monday, January 13th at 5:15 PM PT Ocular to provide enrollment update for SOL-R, Ocular's second registrational trial of AXPAXLI™ in wet AMD, future opportunities for AXPAXLI, and a general corporate overview
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BEDFORD, Mass., Dec. 13, 2024 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ:OCUL, "Ocular" ) , a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye ...
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BEDFORD, Mass., Dec. 10, 2024 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ: OCUL, "Ocular", the "Company" ) , a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and ...
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Ocular Therapeutix ( NASDAQ:OCUL )
BEDFORD, Mass., Dec. 10, 2024 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. OCUL "Ocular", the "Company" ) ) , a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye ...
Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences
BEDFORD, Mass. , Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ: OCUL, "Ocular", the "Company" ) , a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and ...
Ocular Therapeutix ( OCUL ) Reports Q3 Loss, Lags Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -13.04% and 12.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
